ArticleJournal of personalized medicine2021
Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma.
Abstract read
In one paragraph
Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Exploratory Analyses of Circulating Neoplastic-Immune Hybrid Cells as Prognostic Biomarkers in Advanced Intrahepatic Cholangiocarcinoma.International journal of molecular sciences · 2024Trial
- Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- The role of radiotherapy in the management of combined hepatocellular-cholangiocarcinoma: current evidence and future perspectives.Journal of liver cancer · 2026Review
- Research on Targeted Therapy for Malignant Tumors of the Biliary Tract.OncoTargets and therapy · 2026Review
- Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of response.NPJ systems biology and applications · 2025Article
- Construction of Immune Infiltration-Related LncRNA Signatures Based on Machine Learning for the Prognosis in Colon Cancer.Biochemical genetics · 2024Article
- Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases.Liver cancer · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Brian DeDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-3468-3359
Ibrahim Abu-GheidaDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Aashini PatelDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Sylvia S W NgDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Mohamed ZaidDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-8615-2456
Connor P ThunshelleDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Dalia ElganainyDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Kelsey L CorriganDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Michael K RooneyDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Milind JavleDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Kanwal RaghavDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Sunyoung S LeeDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jean-Nicolas VautheyDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ching-Wei D TzengDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hop S Tran CaoDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ethan B LudmirDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-5472-5344
Bruce D MinskyDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Grace L SmithDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Emma B HollidayDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cullen M TaniguchiDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-8052-3316
Albert C KoongDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Prajnan DasDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Eugene J KoayDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-7675-3461
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MClinical Validation Center for Early Detection of Pancreatic CancerU01CA200468 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANIRBAN MAITRA · 2016 to 2026
$11.0MTransport Oncophysics CoreU54CA210181 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI SHEN, HAIFA · 2016 to 2020
$9.3MImaging and Molecular Correlates of Progression in Cystic Neoplasms of the PancreasU01CA196403 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MAITRA, ANIRBAN · 2015 to 2020
$5.8MTranslating Intestinal Radioprotection by EGLN Inhibition to Improve Clinical Outcomes in Unresectable Pancreatic CancerR01CA227517 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOONG, ALBERT · 2019 to 2023
$2.3MNCI NIH HHS P30 CA016672NCI NIH HHS R01 CA227517NCI NIH HHS U01CA196403NCI NIH HHS U01CA200468NCI NIH HHS U54CA210181-01Radiological Society of North America RR2111Radiological Society of North America RSD1429
Abstract
We have previously shown that ablative radiotherapy (A-RT) with a biologically effective dose (BED
Indexed as
cholangiocarcinomageneticgenomicmutationradiotherapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.